I read with great interest the letter of Shi V. Liu about "Rectify the Distorted Microscopic View on Life: an Open Letter to Microbiologists" (Microbe, January 2006, p. 1) and the response by Dennis Hill about "Defining Life Principles" (Microbe, April 2006, p. 159) . Liu described that, with the establishment of microbiology, we have a dichotomous view on life in regard to the observable differences in reproduction patterns of macroorganisms and microorganisms, and that perhaps the microscopic view on life is distorted and requires the formation of a new biology. Hill pointed out that prokaryotes and eukaryotes reproduce differently, and that a particular view of life needs only to be properly refined and should not be too constrictive, but rather be handled with an open mind, thus eliminating the need for a new biology.
We learn from biology courses a great deal about life's unity and life's diversity. We memorize the cell theory, which says that (i) every organism consists of one or more cells, that (ii) the cell is the smallest unit that still displays the properties of life, and (iii) that the continuity of life arises directly from the growth and division of single cells (C. Starr, Basic Concepts in Biology, Thomson Brooks/Cole, 6th edition, 2006) . The biology instructors made us recognize that prokaryotes and eukaryotes are both capable of reproducing, but that they significantly differ in their reproduction patterns. We can define reproduction as the sexual or asexual process by which organisms generate others of the same kind, and we realize that cell division is essentially the bridge between generations. We distinguish three different cell division mechanisms, which are (i) mitosis, a nuclear division mechanism that occurs in somatic (body) cells of all multicelled eukaryotes; (ii) meiosis, a different nuclear division mechanism that functions only in sexual reproduction and precedes the formation of gametes (such as sperms or eggs) or spores; and (iii) the prokaryotic fission which occurs in eubacteria and archaebacteria, and is the basis of asexual reproduction (Starr, Basic Concepts in Biology) . As scientists, we become fascinated with the diversity of reproduction patterns observable in micro-and macroorganisms, yet it seems that the goal of all known reproduction patterns among life forms is the same, which is, to guarantee that life continues into the future beyond the current generation. This, perhaps, is the strongest expression of life's unity. I believe it is important that scientists continuously discuss the topic of the principle(s) of life and analyze new findings to determine whether or not our currently existing hypotheses about life still hold true or need to be modified. year. If 90% of campylobacter infections are from meats, 90% of these are from chicken and half of the resistance is due to macrolide use in poultry, then about 13,000 people (40,000 ϫ 0.9 ϫ 0.9 ϫ 0.5) will have a macrolide-resistant campylobacter infection as a result of macrolide Volume 1, Number 7, 2006 / Microbe Y 303 use in poultry. If we assume that only a small proportion of these people may benefit from macrolide therapy (e.g., 10%the others clear the infection themselves without antibiotics), this then results in about 1,300 people per year with a likely adverse outcome due to macrolide use in poultry; much higher than the 30 people estimated by Hurd.
Hurd estimates that about 634 million poultry are exposed to macrolides (tylosin and tilmicosin) annually in the United States (H. S. Hurd et al., J. Food Prot. 67: 980 -992, 2004) . This allows us to estimate how many people will have an adverse outcome compared to the number of animals receiving macrolides. If in the United States 1,300 people per year have an adverse outcome following macrolide use in 634 million poultry, then about 2 people are likely to have an adverse outcome for every 1 million chickens treated with macrolides. This is a marked improvement on fluoroquinolone use, where 285 people are likely to have an adverse outcome for every 1 million chickens exposed to fluoroquinolones (P. Collignon, Emerg. Infect. Dis. 2005 Nov. 11: 1789 -1790, http://www.cdc.gov/ncidod /eid/vol11no11/04 -0630_05-0652_05 -1022.htm).
Whatever the number of adverse events, antibiotic use in poultry remains of great concern because most of this antibiotic use is needless but they are used in huge quantities (M. Mellon and S. Fondriest, Nucleus 23:1-3, 2001). Most macrolide use in poultry is as a routine in-feed additive for the purpose of growth promotion or disease prevention. This use has relatively little economic benefit to farmers. All recently published large studies of poultry in both Denmark and the U. 1.pdf, 2003) . Indeed, 38% of the poultry in the United States is now produced without the routine use of these antibiotics (12). Tyson Foods the largest U.S. poultry producer has decreased antibiotic use by 93%-from 853,000 pounds in 1997 to just 59,000 in 2004. In 2004, less than 1% of the company's broilers received antibiotics (E. Weise, USA Today, January 24, 2006 January 24, , http://www .usatoday.com/news/health/2006 .
It is appropriate that we do risk calculations such as proposed by Hurd, but we need models that use realistic assumptions. We also need data on the quantities and types antibiotics used. This needs to be made publicly available by the companies supplying them-as was done by Elanco for Hurd's modeling. We also need to stop using large volumes of antibiotics inappropriately. Even if the risk looks very low, when translated to the large populations (e.g., the United States with 300 million), it means that large numbers of people per year have adverse outcomes. We should be able to cut the numbers of people acquiring these resistant infections by 90% of more if we stop using the inappropriate and large-scale use of antibiotics as routine in-feed additives.
Peter Collignon
The Canberra Hospital and Canberra Clinical School, Australian National University and Sydney University Woden, Australia
Coliform Assays: Inadequate and Unwarranted
Professors Doyle and Erickson are to be commended for raising an issue that vexes many microbiologists ("Closing the Door on the Fecal Coliform Assay," Microbe, April 2006, p. 162-163) . This vexing issue is even more serious in the food industry than would be indicated solely by use of the fecal coliform assay, because many food processors specify that total coliform assays be performed on their ingredients and/or finished products.
As indicators of fecal contamination, coliform assays are inadequate and unwarranted for several reasons. Coliform bacteria represent only about half of the genera in the family Enterobacteriaceae, and some of the overt pathogens in this family, e.g., salmonellae, are not coliforms. As is true for the entire family, some coliforms grow primarily on green plants and in other environmental niches. Their presence in a food ingredient or product is not indicative of fecal contamination. Therefore, the public health utility of coliform specifications and assays is sig-nificantly compromised. Their use is increasingly a misuse of resources.
The microbiology professions should work together to eliminate all coliform designations and assay requirements. Our resources could then be focused, when warranted, on assays for indicators or specific pathogens that would more effectively provide public health and food safety assurance. As indicated by Doyle and Erickson, the technological tools to support this change are already available. Furthermore, in today's food industry, such assays are preferably performed for the validation and verification of quality and food safety programs, not for the direct acceptance testing of ingredients or finished products. Optimizing Antibiotic Therapy I am in full agreement with Dr. Hibbard and his recommendation that antimicrobials should be used in combination to reduce the likelihood of resistance selection (Microbe, May 2006, p. 209) . His explanation of bacterial population genetics clearly highlights the issue. Indeed this concept was originally proposed by Paul Ehrlich as early as 1913 (P. Ehrlich, Lancet 1913, p. 455-453) and has been the backbone of antituberculosis therapy for almost 50 years. However the rationale behind the single drug use, often at inappropriate doses for long durations, is not based on science, but most probably on cost or adverse event savings with the logic that in many infections the antibacterials are used to "support" the host defense in combating infections. In many cases this works well to resolve infections but also serves to select the first-step resistant mutants as Dr. Hibbard describes. Karl Drlica's group have espoused a new concept to tackle this issue, the mutant prevention concept wherein they test bacterial populations to determine how much drug it would take to prevent resistance developing by selection of first-step mutants (Y. Dong, X. Zhao, B. N. Kreiswirth, and K. Drlica, Antimicrob. Agents Chemother. 44:2581-2584, 2000). Today, I suspect cost savings and a wary eye towards adverse events are preventing a more complete embrace of the two-or-more-drugs approach. Moreover, if the most pharmacodynamically effective members of a drug class are used (W. M. Scheld, Emerg. Infect. Dis. 9:1-9, 2003) and shown not to be antagonistic to each other then shorter courses maybe possible and overall costs maybe reduced as fewer relapses and follow-up therapy will be required as resistance is kept at bay. As we have few new antibacterials in development we should recall the advice of our predecessors and use this valuable resource in a more thoughtful way.
As Ehrlich said "hit hard, hit fast" to keep resistance away.
